BridgeBio (BBIO) Tanks After Selling Beyonttra Royalty Rights
In a statement, BridgeBio Pharma, Inc.
Bridgebio Pharma Inc. (BBIO)
Market is closed
News
- 1 - 10
- Next >>
Piper Sandler Reaffirms Overweight Rating on BridgeBio Ahead of Phase 3 CALIBRATE Results
BridgeBio Pharma, Inc. (NASDAQ:BBIO) is one of billionaire Stan Druckenmiller’s top stock picks with huge upside potential.
Wolfe Research Initiates Coverage of BridgeBio Pharma (BBIO) with 'Outperform' Rating
BridgeBio Pharma, Inc. (NASDAQ:BBIO) is one of the 10 biotech stocks screaming a buy. On June 17, Wolfe Research initiated coverage of the stock with an ‘Outperform’ rating and a $49 price target.
10 Biotech Stocks Screaming a Buy
The biotech sector has underperformed the overall market. Those are sentiments echoed by JPMorgan analyst Chris Schott, given the 10% year-to-date loss by the SPDR S&P Biotech ETF.
Billionaire Stan Druckenmiller's 10 Stock Picks with Huge Upside Potential
Stanley Druckenmiller, an American billionaire investor, is the founder of Duquesne Capital.
BridgeBio Pharma, Inc. (BBIO) Price Target Raised to $56 from $53 at H.C. Wainwright
BridgeBio Pharma, Inc. (NASDAQ:BBIO) is one of the 13 Biotech Stocks with Huge Upside Potential. In a recent report, Raghuram Selvaraju, an expert at H.C.
13 Biotech Stocks with Huge Upside Potential
The FDA Commissioner Marty Makary stated the FDA will reach its 2025 drug approval targets despite severe workforce reductions.
BMO Maintains Hold on BridgeBio (BBIO) Amid Intensifying Competition
On June 3, BMO Capital Markets analyst Kostas Biliouris reiterated a Hold rating on BridgeBio Pharma Inc. (NASDAQ:BBIO) with an unchanged price target of $37.
BridgeBio's Acoramidis: A Breakthrough in ATTR-CM Treatment
On May 19, BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Q1 2025 Earnings Call Transcript
Operator: Good afternoon. I will be your conference operator today. All lines have been placed on mute to prevent any background noise.
- 1 - 10
- Next >>
Billionaire Hedge Funds
